Saturday 17 October 2026
Export KROS’s income statement to Excel — free account
Keros Therapeutics, Inc.
KROS Healthcare Biotechnology
In the quarter to June 2026, revenue fell 99.8%, EPS fell 90.8% and free cash flow grew 32.2%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
10.66
0.44
−3.96%
Follow KROS
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | 0.00 | 10.95 | 10.01 |
+8 more quarters Free account |
P/S ratio |
— | 6.53 | 3.11 | 2.60 | |
P/FCF ratio |
— | 0.00 | 7.15 | 7.38 | |
P/Operating CF |
— | (61.41) | (27.77) | 197.80 | |
P/B ratio |
— | 0.76 | 2.50 | 0.91 | |
Price to Tangible BV |
— | 0.76 | 2.50 | 0.91 | |
EV/Sales |
— | (1.95) | 1.93 | (0.21) | |
EV/EBITDA |
— | 0.60 | 6.81 | 0.00 | |
EV/Operating CF |
— | 1.13 | 4.38 | (0.57) | |
EV/FCF |
— | 1.11 | 4.44 | (0.58) | |
Quick Ratio |
21.38 | 22.11 | 14.36 | 28.93 | |
Current Ratio |
21.96 | 22.62 | 15.45 | 29.86 | |
Net Debt/EBITDA |
8.44 | 11.05 | 9.96 | 46.27 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.06 | 0.51 | 0.37 | |
Operating CF/Net income |
0.71 | 0.15 | 1.16 | (0.45) | |
Capex/Depreciation |
(0.39) | (0.18) | (0.33) | (0.33) | |
Research and Development Expense of Revenue |
0.00% | 4,386.10% | 4,652.47% | 136.86% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 2,764.85% | 3,050.13% | 71.01% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 1,689.10% | 1,897.40% | 27.95% | |
Graham Net Nets |
— | 1.22 | 0.37 | 1.06 | |
Graham Number |
— | 0.00 | 18.46 | 24.81 | |
Earnings Yield |
— | (27.26%) | 9.14% | 9.99% | |
Free Cash Flow Yield |
— | (26.88%) | 13.98% | 13.55% | |
Revenue per Share |
0.00 | 0.02 | 0.01 | 0.35 | |
Operating CF per Share |
(1.03) | (0.18) | (0.73) | 0.08 | |
Capex per Share |
(0.01) | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(1.04) | (0.18) | (0.74) | 0.08 | |
Cash per Share |
13.01 | 14.34 | 7.72 | 17.07 | |
Shareholders Equity per Share |
13.25 | 14.55 | 8.14 | 17.32 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
13.25 | 14.55 | 8.14 | 17.32 | |
Free Cash Flow |
(20.58) | (3.60) | (27.43) | 3.12 | |
Working Capital |
254.73 | 277.82 | 295.02 | 695.22 | |
Capital Expenditures |
(0.15) | (0.07) | (0.13) | (0.13) | |
Net Current Asset Value |
241.60 | 264.01 | 280.55 | 680.10 | |
EV/EBIT |
— | 0.59 | 6.96 | 0.00 | |
Capex to Sales |
0.00 | 0.20 | 0.35 | 0.01 | |
Price to Operating Income |
— | 0.00 | 11.22 | 14.74 | |
| Other line items | |||||
Average Receivables |
9.03 | 9.97 | 4.28 | 1.94 | |
Average Payables |
3.54 | 4.06 | 3.28 | 3.64 | |
Average Assets |
522.38 | 548.43 | 476.95 | 661.03 | |
Average Common Equity |
484.53 | 507.25 | 437.34 | 618.21 |
Columns are period end dates